Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.1093/annonc/mdi110 | Use of complementary and alternative medicine in cancer patients: a European survey |
| https://doi.org/10.1038/leu.2017.138 | Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study |
| https://doi.org/10.1007/s00520-005-0883-7 | Complementary and alternative medicine use in breast cancer patients in Europe |
| https://doi.org/10.1097/cji.0b013e31821dcb31 | Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma |
| https://doi.org/10.1111/j.1600-0609.2010.01533.x | Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study |
| https://doi.org/10.1111/j.1600-0609.2011.01599.x | Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma |
| https://doi.org/10.1093/annonc/mdx440.030 | Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) |
| https://doi.org/10.1097/cco.0b013e32833de186 | Circulating tumor cells and emerging blood biomarkers in breast cancer |
| https://doi.org/10.1097/cco.0b013e328344f527 | Modern treatment for nasopharyngeal carcinoma: current status and prospects |
| https://doi.org/10.1016/j.ctcp.2004.12.005 | Complementary and alternative medicine use in patients with haematological malignancies in Europe |
| https://doi.org/10.1002/bjs.9624 | Effect of hospital volume on quality of care and outcome after rectal cancer surgery |
| https://doi.org/10.1182/blood.v118.21.476.476 | Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial |
| https://doi.org/10.1097/cco.0b013e3283139173 | Hereditary breast cancer: from bench to bedside |
| https://doi.org/10.1007/s41999-018-0141-4 | The SARCUS project: evidence-based muscle assessment through ultrasound |
| https://doi.org/10.1007/s41999-018-0110-y | The relation between mortality, intramuscular adipose tissue and sarcopenia in hospitalized geriatric patients |
| https://doi.org/10.1007/s00428-024-04012-2 | Obstacles and drivers in the adoption of Standardized Structured Reporting (SSR): insights from pathologists |
| https://doi.org/10.1182/blood.v128.22.4414.4414 | Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study |
| https://doi.org/10.1210/clinem/dgad159 | Early GH Treatment Is Effective and Well Tolerated in Children With Turner Syndrome: NordiNet® IOS and Answer Program |
| https://doi.org/10.1016/j.ejca.2024.113561 | Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy |
| https://doi.org/10.1182/blood.v112.11.650.650 | Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma |
| https://doi.org/10.1097/00005373-199603001-00048 | External Fixation in War Traumatology |
| https://doi.org/10.1182/blood.v112.11.54.54 | Darbepoetin-Alfa and I.V. Iron Administration after Autologous Hematopoietic Stem Cell Transplantation: A Prospective Randomized Multicenter Trial |
| https://doi.org/10.1182/blood.v124.21.80.80 | Safety and Efficacy in the Stratus (MM-010) Trial, a Single-Arm Phase 3b Study Evaluating Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma |
| https://doi.org/10.1182/blood.v112.11.2778.2778 | Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone |
| https://doi.org/10.1016/j.suronc.2020.10.014 | Diagnosis, pathophysiology, and treatment of SIRT-induced gastroduodenal ulcers: A systematic literature review |
| https://doi.org/10.1038/s41409-019-0458-8 | Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres |
| https://doi.org/10.1182/blood.v110.11.76.76 | MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma. |
| https://doi.org/10.1182/blood.v114.22.3859.3859 | Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use. |
| https://doi.org/10.1182/blood.v112.11.1727.1727 | Bortezomib–Melphalan–Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients with Impaired Renal Function: Cohort Analysis of the Phase III VISTA Study. |
| https://doi.org/10.1158/0008-5472.sabcs-09-203 | SUCON Trial (SUnitinib CONsolidation Therapy in Metastatic Breast Cancer): A Belgian Multicenter Phase II Randomized Trial in Her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy with Sunitinib after Objective Response to Taxane Chemotherapy. |
| https://doi.org/10.5334/jbr-btr.1004 | A New Editor-in-Chief Takes Over |
| https://doi.org/10.1182/blood.v124.21.4770.4770 | Outcomes for Older Patients in Stratus (MM-010), a Single-Arm, and Phase 3b Study of Pomalidomide + Low-Dose Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma |
| https://doi.org/10.1200/jco.2018.36.15_suppl.tps2615 | An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology. |
| https://doi.org/10.1182/blood.v108.11.5241.5241 | Palifermin Treatment in Patients Receiving High Dose Melphalan or BEAM Prior to Autologous Peripheral Blood Stem-Cell Transplantation. |
| https://doi.org/10.1182/blood.v112.11.1741.1741 | Erythropoiesis-Stimulating Agents Do Not Adversely Affect Long-Term Outcomes Nor Increase the Risk of Thromboembolic Events in Multiple Myeloma Patients Treated in the Phase III VISTA Trial. |
| [Recommendations for the prevention of cardiovascular diseases in clinical practice]. | |
| https://doi.org/10.21203/rs.3.rs-1584056/v1 | Heterozygote germline mutations in Homologous Recombination core genes can predict for pathologic complete response in early triple negative breast cancer. |
| https://doi.org/10.1016/j.jgo.2014.09.104 | Geriatric interventions in older cancer patients: International society of geriatric oncology (siog) recommendations |
| https://doi.org/10.1158/1538-7445.sabcs16-p5-16-06 | Abstract P5-16-06: Neoadjuvant weekly carboplatin and paclitaxel followed by dose dense epirubicin and cyclophosphamide in triple negative breast cancer patients: A single arm phase II study from the Belgian Society of Medical Oncology |
| [Recommendations for the prevention of cardiovascular diseases in clinical practice. Belgian Working Group on Prevention of Ccardiovascular Diseases]. | |
| https://doi.org/10.15406/hpmij.1.1 | |
| https://doi.org/10.1200/jco.2022.40.16_suppl.e24053 | Short and medium-term outcomes of patients with solid cancer hospitalized with COVID-19 in Belgium according to cancer diagnosis and treatment characteristics. |
| https://doi.org/10.1016/j.suronc.2022.101898 | Corrigendum to “Diagnosis, pathophysiology, and treatment of SIRT-induced gastroduodenal ulcers: A systematic literature review” [Surg. Oncol. 35 (2020) 520–526] |
| https://doi.org/10.1007/s00520-024-08319-3 | Correction to: Complementary and alternative medicine use in breast cancer patients in Europe |
| https://doi.org/10.1080/17843286.2026.2613903 | Effective prompt design for large language models in clinical practice |